Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships : Insights from Roche’s Endocannabinoid System Projects

Thumbnail Image
2024_499.pdf (783.65 KB)
Identifiers
URI: https://hdl.handle.net/10641/7717
ISSN: 0009-4293
DOI: 10.2533/chimia.2024.499

Publication date

2024

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The endocannabinoid system (ECS) is a critical regulatory network composed of endogenous cannabinoids (eCBs), their synthesizing and degrading enzymes, and associated receptors. It is integral to maintaining homeostasis and orchestrating key functions within the central nervous and immune systems. Given its therapeutic significance, we have launched a series of drug discovery endeavors aimed at ECS targets, including peroxisome proliferator-activated receptors (PPARs), cannabinoid receptors types 1 (CB1R) and 2 (CB2R), and monoacylglycerol lipase (MAGL), addressing a wide array of medical needs. The pursuit of new therapeutic agents has been enhanced by the creation of specialized labeled chemical probes, which aid in target localization, mechanistic studies, assay development, and the establishment of biomarkers for target engagement. By fusing medicinal chemistry with chemical biology in a comprehensive, translational end-to-end drug discovery strategy, we have expedited the development of novel therapeutics. Additionally, this strategy promises to foster highly productive partnerships between industry and academia, as will be illustrated through various examples.

Doctoral program

Description

Publisher Copyright: © U. Grether et al.

Keywords

Academia-industry collaboration, CBR, Endocannabinoid system, Labeled chemical probe, MAGL, PPAR, General Chemistry, Journal Article, Yes, yes

Citation

Aebi, J, Atz, K, Ametamey, S M, Benz, J, Blaising, J, Butini, S, Campiani, G, Carreira, E M, Collin, L, de Lago, E, Gazzi, T, Gertsch, J, Gobbi, L, Guba, W, Fernández-Ruiz, J, Fingerle, J, Haider, A, He, Y, Heitman, L H, Honer, M, Hunziker, D, Kuhn, B, Maccarrone, M, Märki, H P, Martin, R E, Mohr, P, Mu, L, Nazaré, M, Nippa, D F, Oddi, S, O’Hara, F, Pacher, P, Romero, J, Röver, S, Rufer, A C, Schibli, R, Schneider, G, Stepan, A F, Sykes, D A, Ullmer, C, van der Stelt, M, Veprintsev, D B, Wittwer, M B & Grether, U 2024, 'Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships : Insights from Roche’s Endocannabinoid System Projects', Chimia, vol. 78, no. 7-8, pp. 499-512. https://doi.org/10.2533/chimia.2024.499

Collections

FACULTAD DE CIENCIAS EXPERIMENTALES